Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 5, 2013, Pages 1922-1939

  Morales, Guillermo A ^a,c   Garlich, Joseph R ^b,c   Su, Jingdong ^c   Peng, Xiaodong ^c   Newblom, Jessica ^c   Weber, Kevin ^c   Durden, Donald L ^b,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b SignalRx Pharmaceuticals   (United States)

^c Semafore Pharmaceuticals Inc   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 MORPHOLINO 3 (PYRIDIN 3 YL) 7H THIENO[3,2 B]PYRAN 7; 5 MORPHOLINO 3 PHENYL 7H THIENO[3,2 B]PYRAN 7; LAPATINIB; N (4 (5 MORPHOLINO 7 OXO 7H THIENO[3,2 B]PYRAN 3 YL) PHENYL)NICOTINAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PYRAN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CHROMONES; ENZYME INHIBITORS; HUMANS; MCF-7 CELLS; MORPHOLINES; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 84875139575     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301522m     Document Type: Article

References (48)

1. Shuttleworth, S.; Silva, F.; Tomassi, C.; Cecil, A.; Hill, T.; Rogers, H.; Townsend, P. Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases Prog. Med. Chem. 2009, 48, 81-131
2. Castellino, R. C.; Muh, C. R.; Durden, D. L. PI-3 kinase-PTEN signaling node: an intercept point for the control of angiogenesis Curr. Pharm. Des. 2009, 15, 380-388
3. Dienstmann, R.; Rodon, J.; Markman, B.; Tabernero, J. Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2. Recent Pat. Anticancer Drug Discovery 2011, 6, 210-36
4. Markman, B.; Dienstmann, R.; Tabernero, J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs Oncotarget 2010, 1, 530-543
5. Jarvis, L. PI3K at the clinical crossroads Chem. Eng. News 2011, 89, 15-19
6. Pezet, S.; Marchand, F.; D'Mello, R.; Grist, J.; Clark, A. K.; Malcangio, M.; Dickenson, A. H.; Williams, R. J.; McMahon, S. B. Phosphatidylinositol 3-kinase is a key mediator of central sensitization in painful inflammatory conditions J. Neurosci. 2008, 28, 4261-4270
7. Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol. Cancer Ther. 2004, 3, 763-772 (Pubitemid 39193758)
8. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4 H -1-benzopyran-4-one (LY294002) J. Biol. Chem. 1994, 269, 5241-5248
9. Walker, E. H.; Pacold, M. E.; Perisic, O.; Stephens, L.; Hawkins, P. T.; Wymann, M. P.; Williams, R. L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine Mol. Cell 2000, 6, 909-919
10. Maira, S. M.; Furet, P.; Stauffer, F. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway Future Med. Chem. 2009, 1, 137-155
11. Knight, Z. A.; Shokat, K. M. Chemically targeting the PI3K family Biochem. Soc. Trans. 2007, 35, 245-249 (Pubitemid 46596480)
12. Garlich, J. R.; De, P.; Dey, N.; Su, J. D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G. B.; Kundra, V.; Shu, H. K.; Peng, Q.; Durden, D. L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity Cancer Res. 2008, 68, 206-215 (Pubitemid 351380122)
13. Foukas, L. C.; Berenjeno, I. M.; Gray, A.; Khwaja, A.; Vanhaesebroeck, B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 11381-11386
14. Edling, C. E.; Selvaggi, F.; Buus, R.; Maffucci, T.; Di Sebastiano, P.; Friess, H.; Innocenti, P.; Kocher, H. M.; Falasca, M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer Clin. Cancer Res. 2010, 16, 4928-4937
15. Fruman, D. A.; Rommel, C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic Cancer Discovery 2011, 1, 562-572
16. Jamieson, S.; Flanagan, J. U.; Kolekar, S.; Buchanan, C.; Kendall, J. D.; Lee, W. J.; Rewcastle, G. W.; Denny, W. A.; Singh, R.; Dickson, J.; Baguley, B. C.; Shepherd, P. R. A drug targeting only p110alpha can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types Biochem. J. 2011, 438, 53-62
17. Brana, I.; Siu, L. L. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment BMC Med. 2012, 10, 161
18. Workman, P.; Clarke, P. A.; Raynaud, F. I.; van Montfort, R. L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic Cancer Res. 2010, 70, 2146-2157
19. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 2000, 351, 95-105
20. Jacobs, M. D.; Black, J.; Futer, O.; Swenson, L.; Hare, B.; Fleming, M.; Saxena, K. Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002 J. Biol. Chem. 2005, 280, 13728-13734 (Pubitemid 40517268)
21. Rosenzweig, K. E.; Youmell, M. B.; Palayoor, S. T.; Price, B. D. Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay Clin. Cancer Res. 1997, 3, 1149-1156 (Pubitemid 27319761)
22. Brunn, G. J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J. C., Jr.; Abraham, R. T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002 EMBO J. 1996, 15, 5256-5267 (Pubitemid 26336209)
23. Yuan, J. H.; Feng, Y.; Fisher, R. H.; Maloid, S.; Longo, D. L.; Ferris, D. K. Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase Mol. Cancer Res. 2004, 2, 417-426 (Pubitemid 39031075)
24. Kong, D.; Dan, S.; Yamazaki, K.; Yamori, T. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39 Eur. J. Cancer 2010, 46, 1111-1121
25. Poh, T. W.; Pervaiz, S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway Cancer Res. 2005, 65, 6264-6274 (Pubitemid 40994412)
26. Imai, Y.; Yoshimori, M.; Fukuda, K.; Yamagishi, H.; Ueda, Y. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation Oncol. Rep. 2012, 27, 1703-1709
27. Bondar, V. M.; Sweeney-Gotsch, B.; Andreeff, M.; Mills, G. B.; McConkey, D. J. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo Mol. Cancer Ther. 2002, 1, 989-997
28. Hu, L.; Hofmann, J.; Lu, Y.; Mills, G. B.; Jaffe, R. B. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Res. 2002, 62, 1087-1092 (Pubitemid 34160292)
29. Mahadevan, D.; Chiorean, E. G.; Harris, W. B.; Von Hoff, D. D.; Stejskal-Barnett, A.; Qi, W.; Anthony, S. P.; Younger, A. E.; Rensvold, D. M.; Cordova, F.; Shelton, C. F.; Becker, M. D.; Garlich, J. R.; Durden, D. L.; Ramanathan, R. K. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies Eur. J. Cancer 2012, 48, 3319-3327
30. Mahadevan, D.; Chiorean, E. G.; Harris, W. B.; Von Hoff, D. D.; Garlich, J. R.; Ramathan, R. K.; Phase, I. Study of the multikinase prodrug SF1126 in solid tumors and B cell malignancies. 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, June 3-7, 2011, p 3015.
31. Arai, N.; Miyaoku, T.; Teruya, S.; Mori, A. Synthesis of thiophene derivatives via palladium-catalyzed coupling reactions Tetrahedron Lett. 2008, 49, 1000-1003
32. Hook, B. B.; Cortizo, L.; Johansson, A. M.; Westlind-Danielsson, A.; Mohell, N.; Hacksell, U. Derivatives of (R)- and (S)-5-fluoro-8-hydroxy-2- (dipropylamino)tetralin: synthesis and interactions with 5-HT1A receptors J. Med. Chem. 1996, 39, 4036-4043 (Pubitemid 26327440)
33. Liu, Y.; Yu, H.; Mohell, N.; Nordvall, G.; Lewander, T.; Hacksell, U. Derivatives of cis -2-amino-8-hydroxy-1-methyltetralin: mixed 5-HT1A-receptor agonists and dopamine D2-receptor antagonists J. Med. Chem. 1995, 38, 150-160
34. Larhed, M.; Hallberg, A. Microwave-Promoted Palladium-Catalyzed Coupling Reactions J. Org. Chem. 1996, 61, 9582-9584 (Pubitemid 127562828)
35. Han, M.; Zhang, J. Z. Class I phospho-inositide-3-kinases (PI3Ks) isoform-specific inhibition study by the combination of docking and molecular dynamics simulation J. Chem. Inf. Model 2010, 50, 136-145
36. Frederick, R.; Denny, W. A. Phosphoinositide-3-kinases (PI3Ks): combined comparative modeling and 3D-QSAR to rationalize the inhibition of p110alpha J. Chem. Inf. Model 2008, 48, 629-638 (Pubitemid 351535430)
37. Lannutti, B. J.; Meadows, S. A.; Herman, S. E.; Kashishian, A.; Steiner, B.; Johnson, A. J.; Byrd, J. C.; Tyner, J. W.; Loriaux, M. M.; Deininger, M.; Druker, B. J.; Puri, K. D.; Ulrich, R. G.; Giese, N. A. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 2011, 117, 591-594
38. Shojaei, F.; Ferrara, N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies Drug Resist. Updat. 2008, 11, 219-230
39. Shojaei, F.; Ferrara, N. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells Cancer Res. 2008, 68, 5501-5504
40. Conley, S. J.; Gheordunescu, E.; Kakarala, P.; Newman, B.; Korkaya, H.; Heath, A. N.; Clouthier, S. G.; Wicha, M. S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 2784-2789
41. Korkaya, H.; Paulson, A.; Charafe-Jauffret, E.; Ginestier, C.; Brown, M.; Dutcher, J.; Clouthier, S. G.; Wicha, M. S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling PLoS Biol. 2009, 7, e1000121
42. Schmidt, C. Lapatinib study supports cancer stem cell hypothesis, encourages industry research J. Natl. Cancer Inst. 2008, 100, 694-695
43. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity Mol. Cancer Ther. 2008, 7, 1851-1863
44. Mukherjee, B.; Tomimatsu, N.; Amancherla, K.; Camacho, C. V.; Pichamoorthy, N.; Burma, S. The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses Neoplasia 2012, 14, 34-43
45. Morales, G. A.; Garlich, J. R.; Su, J. D.; Weber, K. T. Novel compound class of designed PI3K pan and isoform-selective inhibitors. 7th International Congress on Targeted Therapies in Cancer, Washington, DC, August 22-24, 2008.
46. Morales, G.; Garlich, J.; Newblom, J.; Peng, X.; Su, J.; Weber, K. SFP6: a new compound class of designed pan- and isoform-selective PI3-kinase small molecule inhibitors. AACR Special Conference on Targeting the PI-3 Kinase Pathway in Cancer, Cambridge, MA, November 11-14, 2008.
47. Barbone, D.; Yang, T. M.; Morgan, J. R.; Gaudino, G.; Broaddus, V. C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids J. Biol. Chem. 2008, 283, 13021-13030
48. Phillips, T. M.; McBride, W. H.; Pajonk, F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation J. Natl. Cancer Inst. 2006, 98, 1777-1785 (Pubitemid 46017929)